Prelude announced the departure of President and CMO Jane Huang, M.D. to pursue other opportunities. Victor Sandor, M.D.C.M., former CMO of Array BioPharma and current Prelude board member and chair of the Science and Technology Committee, will provide strategic and operational oversight of clinical development as the Company advances KAT6A towards first-in-human studies, and its JAK2 program.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRLD:
- Prelude Therapeutics announces publication of abstracts for ASH meeting
- Prelude Therapeutics Advances with PRT7732 in Targeted Cancer Therapy
- Prelude Therapeutics Appoints Katina Dorton to Board
- Prelude Therapeutics appoints Katina Dorton to board of directors
- Prelude Therapeutics: Promising SMARCA2-Targeted Degraders and Positive Outlook Support Buy Rating